Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

NEXT STORY
Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
PREV STORY
The Worldwide Biosimilars Industry is Expected to Reach $44.7 Billion by 2026
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

The CARBALIVE Consortium announces positive results of a Phase 2 equivalent trial of engineered macroporous carbons as a novel treatment for cirrhosis

author_avatar
NASDAQ Market News

Hemispherx Updates Stockholders, Highlighting Ampligen’s Role in Enhancing Immunotherapeutic Therapies

OCALA, Fla., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), ...

author_avatar
NASDAQ Market News

Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19

author_avatar
NASDAQ Market News